الفهرس 
ENGLISH ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
An autoimmune chronic condition called oral lichen planus (OLP) caused by cytotoxic T-lymphocytes . Matrix metalloproteinase-9 enzyme is considered a reliable biomarker of inflammation. Zinc is pro-antioxidant with various benefits on human health and has been found to participate oral lichen planus treatment.
The current study intended to examine and assess clinically the effectiveness of adding oral zinc intake to the conventional therapy and the conventional therapy alone in the treatment of erosive OLP (EOLP).Additionally, to measure biochemically MMP-9 levels in saliva before and after both treatment modalities
In this randomized controlled clinical trial, 22 patients clinically and histopathologically were diagnosed as EOLP. Patients were treated by different modalities for which they were split into two equal groups:
Test (group I): received oral systemic zinc picolinate capsule 50mg as a single morning dose, in addition to application of topical corticosteroids twice daily for 6 weeks.
Control (group II): Patients were instructed to apply topical corticosteroids twice daily for 6 weeks.
Results:Test group showed a significant lowering in Thongprasom et al score after 6 weeks, a significant reduction in numerical rating scale (NRS) after 6 and 12 weeks, and a significant reduction in MMP-9 levels from baseline to weeks 12 as compared to the control group. No significant reduction was noted in the lesion surface area in each group. Correlations between lesion surface area and biochemical outcomes revealed a strong positive association between disease severity and MMP-9 levels.